Showing 4011-4020 of 9301 results for "".
- NuFace Names New CEOhttps://practicaldermatology.com/news/nuface-names-new-ceo/2460504/Michael Larrain is the new Chief Executive Officer at NuFACE. Tera Peterson, former CEO, will remain at the company as Co-Founder, Chairman of the Board and Chief Creative Officer. Larrain was CEO at PCA Skin and held several executive positions at L'Oreal, including President of the Active Cosme…
- Lumenis Introduces NuEra Tighthttps://practicaldermatology.com/news/lumenis-introduces-nuera-tight/2460502/Lumenis is rolling out the NuEra Tight with FocalRF technology for body contouring. NuEra Tight will be available worldwide starting with the United States in August 2020 and Europe, the Middle East and Asia later this year. "Radio Frequency treatments are among the most requested aesthetic thera…
- InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technologyhttps://practicaldermatology.com/news/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology/2460501/InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform. Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its 40 gold-coated pins. The new Morpheus8 Body will…
- Merz Aesthetics Rolls Out “Confidence to Be” Branding Platform and Other Changeshttps://practicaldermatology.com/news/merz-aesthetics-rolls-outconfidence-to-be-branding-platform-and-other-changes/2460497/Merz Aesthetics is launching its new “confidence to be” branding platform following the conclusion of the company’s reorganization. Merz is now three independently operating businesses: medical aesthetics, therapeutics and consumer care. “The new brand for Merz Aesthetics is an expression of our …
- FDA Fast Tracks Leo Pharma’s Delgocitinib Cream for Hand Eczemahttps://practicaldermatology.com/news/fda-fast-tracks-leo-pharmas-delgocitinib-cream-for-hand-eczema/2460490/Delgocitinib cream, Leo Pharma’s investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are currently no treatmen…
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the in…
- And the Winner Is...Dr. Junko Takeshita of University of Pennsylvania Wins 2020 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/and-the-winner-isdr-junko-takeshita-of-university-of-pennsylvania-wins-2020-childhood-eczema-challenge-grant/2460481/The National Eczema Association (NEA) and the Pediatric Dermatology Research Alliance’s (PeDRA) inaugural Childhood Eczema Challenge Grant goes to Junko Takeshita, MD, PhD, MSCE of the University of Pennsylvania Perelman School of Medicine. The grant of $50,000 will commence in August 2020. NEA a…
- FirstDerm Launches @AutodermBothttps://practicaldermatology.com/news/firstderm-launches-at-autodermbot/2460479/FirstDerm.com is launching a new artificial intelligence (AI) skin @autodermbot on messenger app Telegram. With the AutodermBot, 400 million Telegram users now have access to a search engine on the most common skin diseases. Autoderm is an “API as a Service” that provides accurate search results …
- Win for MC2 Therapeutics: Wynzora Cream Approved for Adults with Psoriasishttps://practicaldermatology.com/news/win-for-mc2-therapeutics-wynzora-cream-approved-for-adults-with-psoriasis/2460476/FDA has approved Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. The approval is based on results of the US Phase 3 clinical trial against active comparat…
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of Tremfya in PsA have been demonstrated in two pivo…